SKLB-197是一種有效且高度選擇性的ATR抑製劑，PK研究通過hjc黄金城進行

Ataxia telangiectasia mutated and Rad3-related (ATR) kinase is an important regulator of the DNA damage response, especially in response to replication stress. SKLB-197 is a potent and highly selective ATR inhibitor with an IC50 value of 13 nM. SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.

Reference

Huachao Bin, et al. Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo. Eur J Med Chem. 2022 Mar 15;232:114187. doi: 10.1016/j.ejmech.2022.114187.